Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Phase 1 study of PTI-808 drug and triple combination in healthy adults and then in adults with cystic fibrosis , protocol number Proteostasis PTI-808-01

  Parts 1 and 2 of this study will take place in healthy volunteers. Part 3 of this study is taking place in adults with cystic fibrosis at multiple care centers across the U.S. It will look at the safety, tolerability, and how the body processes the drug in multiple ascending doses of PTI-808 and PTI-808 together with PTI-428 and PTI-801.

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    10

  • Length of Participation:

    56 days

• Mucociliary ClearanceEnrolling

  Cohorts 1 and 2 of a study to evaluate inhaled QBW276 in adults with CF , protocol number Novartis CQBW276X2201

  This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. This study will look at the safety and tolerability of the inhaled drug QBW276 as well as how the body processes the drug.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    6

  • Length of Participation:

    14 days

• Anti-InflammatoryEnrolling

  Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number Laurent LAU-14-01

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 90%

  • Number of Visits:

    6

  • Length of Participation:

    189 days

• Anti-InfectiveEnrolling

  STOP 2: Treatment of pulmonary exacerbations in people with CF , protocol number STOP2-IP-15

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of different lengths of IV treatment for pulmonary exacerbations in people with CF.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    3

  • Length of Participation:

    35 days

• Nutritional-GIEnrolling

  Phase 2 study of oral glutathione in children with cystic fibrosis , protocol number GROW-IP-16

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug glutathione in children with cystic fibrosis.

  • Age:

    24 Months to 10 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    6 months

• ObservationalEnrolling

  Phase 4 TOBI Podhaler observational study , protocol number Novartis CTBM100C2407

  This study is taking place at multiple care centers across the U.S. It will look at the effectiveness and long term safety of the TOBI Podhaler and other FDA-approved inhaled antipseudomonal drugs.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 80%

  • Number of Visits:

    22

  • Length of Participation:

    60 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.